Instrument Inactif

Autres langues Biondvax Pharmaceuticals Ltd Other OTC

Actions

Recherche biotechnologique et médicale

Autres langues

16/07/19	Biondvax Pharmaceuticals : Announces Rights Offering Fully Subscribed at US$20 Million
08/07/19	Biondvax Pharmaceuticals : First Participant Enrolled in Second Cohort of BiondVax’s Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial
26/06/19	Biondvax Pharmaceuticals : European Investment Bank VP attends Signature Event at BiondVax Extending Financing Agreement with BiondVax to €24 million
18/06/19	Biondvax Pharmaceuticals : Patent Covering Manufacturing Process of BiondVax’s M-001 Universal Flu Vaccine Allowed in USA and Japan
10/06/19	Biondvax Pharmaceuticals : Announces Rights Offering in Support of Ongoing Pivotal, Clinical Efficacy Phase 3 Trial of the M-001 Universal Flu Vaccine and Scale Up of Manufacturing Process
22/04/19	Biondvax Pharmaceuticals : European Investment Bank (EIB) extends financing agreement to €24 million total in support of BiondVax’s universal flu vaccine ongoing pivotal Phase 3 clinical trial
21/03/19	Biondvax Pharmaceuticals : Last participant out in USA Phase 2 clinical trial of BiondVax’s M-001 Universal Influenza Vaccine candidate
26/11/18	Biondvax Pharmaceuticals : CEO to Present at “World Vaccine Congress 2018 San Diego” about ’s Phase 3 Universal Flu Vaccine Candidate
13/11/18	Biondvax Pharmaceuticals : Announces Third Quarter 2018 Financial Results
24/10/18	Biondvax Pharmaceuticals : Universal Flu Vaccine Phase 3 Clinical Trial Completes First Season’s Enrollment of 4,098 Participants
28/06/18	Biondvax Pharmaceuticals : Corporate Biotech Executive Mark Germain Joins BiondVax’s Board of Directors
05/12/17	Biondvax Pharmaceuticals : CEO Issues Letter to Shareholders
28/11/17	Biondvax Pharmaceuticals : Provides Third Quarter 2017 Financial Results and Update
20/11/17	Biondvax Pharmaceuticals : and NIH sign Clinical Trial Agreement for a Phase 2 trial in the U.S. with ’s Universal Flu Vaccine
14/09/17	Biondvax Pharmaceuticals : Announces Pricing of Public Offering of American Depositary Shares
13/09/17	Biondvax Pharmaceuticals : Announces Public Offering of American Depositary Shares
20/07/17	Biondvax Pharmaceuticals : Reports Positive Phase 2b Clinical Trial Results for its Universal Flu Vaccine
28/06/17	Biondvax Pharmaceuticals : CEO Provides First Half 2017 General Corporate Update
21/06/17	Biondvax Pharmaceuticals : European Investment Bank (EIB) supports Late-Stage Development and Production of BiondVax’s Universal Flu Vaccine Candidate under Horizon 2020 Initiative
30/05/17	Biondvax Pharmaceuticals : Announces First Quarter 2017 Financial Results and Update
28/04/17	Biondvax Pharmaceuticals : Announces Fourth Quarter and Full Year 2016 Financial Results and Update
30/03/17	Biondvax Pharmaceuticals : Approved for Grant from Israel’s Ministry of Economy and Industry to Build Facility for Commercial Scale Production of its Universal Flu Vaccine
13/03/17	Biondvax Pharmaceuticals : publishes regulatory approval strategy for novel universal flu vaccines in Future Virology journal
12/01/17	Back to the Future: Study Published in Vaccine Journal Indicates BiondVax’s Universal Flu Vaccine Candidate May Cover Strains Which Don’t Yet Exist
28/11/16	Biondvax Pharmaceuticals : Announces Third Quarter 2016 Financial Results and Update